HARMONY BIOSCIENCES HOLDINGS, INC. Proceeds from Long-Term Debt Issued
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Proceeds from Long-Term Debt Issued of $200.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-02-24
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2020-09-30 was $0.00.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $200.00M.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2021 was $200.00M, a 0.00% change from fiscal 2020.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $200.00M, a 100.00% increase from fiscal 2019.
- HARMONY BIOSCIENCES HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $100.00M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $200.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $200.00M 10-Q · filed 2024-10-29 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $200.00M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $200.00M 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $0.00 derived: sum of 2 quarters · filed 2023-02-21 | $0.00 derived: sum of 3 quarters · filed 2023-02-21 | $200.00M 10-K · filed 2023-02-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $200.00M 10-Q · filed 2021-11-09 | $225.00M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $200.00M 10-Q · filed 2021-08-10 | $225.00M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2020-03-31 | $200.00M 10-Q · filed 2021-05-11 | $225.00M derived: sum of 2 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $100.00M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $75.00M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |